PL2549995T3 - Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabiny - Google Patents
Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabinyInfo
- Publication number
- PL2549995T3 PL2549995T3 PL11714880T PL11714880T PL2549995T3 PL 2549995 T3 PL2549995 T3 PL 2549995T3 PL 11714880 T PL11714880 T PL 11714880T PL 11714880 T PL11714880 T PL 11714880T PL 2549995 T3 PL2549995 T3 PL 2549995T3
- Authority
- PL
- Poland
- Prior art keywords
- anatabine
- inflammation
- treatment
- synthesis methods
- synthesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/729,346 US8207346B2 (en) | 2010-03-23 | 2010-03-23 | Methods of synthesizing anatabine |
| US38381110P | 2010-09-17 | 2010-09-17 | |
| US38444710P | 2010-09-20 | 2010-09-20 | |
| US201161439473P | 2011-02-04 | 2011-02-04 | |
| US201161439483P | 2011-02-04 | 2011-02-04 | |
| EP11714880.9A EP2549995B1 (en) | 2010-03-23 | 2011-03-23 | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
| PCT/US2011/029613 WO2011119722A2 (en) | 2010-03-23 | 2011-03-23 | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2549995T3 true PL2549995T3 (pl) | 2021-09-27 |
Family
ID=44201080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11714880T PL2549995T3 (pl) | 2010-03-23 | 2011-03-23 | Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabiny |
Country Status (8)
| Country | Link |
|---|---|
| EP (4) | EP2549995B1 (pl) |
| AU (5) | AU2011232478A1 (pl) |
| CA (1) | CA2794097C (pl) |
| DK (1) | DK2549995T3 (pl) |
| ES (1) | ES2869851T3 (pl) |
| PL (1) | PL2549995T3 (pl) |
| PT (1) | PT2549995T (pl) |
| WO (1) | WO2011119722A2 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140124354A (ko) * | 2011-08-29 | 2014-10-24 | 알씨피 디벨롭먼트, 인크. | 항염증 지원용 제품 |
| EP2793026A1 (en) | 2013-04-18 | 2014-10-22 | Centre National de la Recherche Scientifique (CNRS) | New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation |
| ES2964561T3 (es) * | 2018-12-17 | 2024-04-08 | Philip Morris Products Sa | Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable de este |
| US20230233459A1 (en) | 2020-06-15 | 2023-07-27 | Philip Morris Products S.A. | Anatabine powder compositions |
| CN116171149A (zh) | 2020-09-03 | 2023-05-26 | 菲利普莫里斯生产公司 | 喷雾干燥的低吸湿性活性粉末组合物 |
| BR112023001929A2 (pt) | 2020-09-03 | 2023-03-14 | Philip Morris Products Sa | Composições em pó ativas de baixa higroscopicidade |
| MX2023002465A (es) | 2020-09-03 | 2023-03-23 | Philip Morris Products Sa | Composiciones en polvo activas de baja higroscopicidad secadas por congelacion. |
| CN113880802A (zh) * | 2021-11-09 | 2022-01-04 | 深圳萨特瓦生物科技有限公司 | 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法 |
| WO2023117661A1 (en) | 2021-12-20 | 2023-06-29 | Philip Morris Products S.A. | Increasing anatabine in tobacco leaf by regulating methyl putrescine oxidase |
| CN115594662A (zh) * | 2022-10-19 | 2023-01-13 | 昆明理工大学（Cn） | 一种(s)-烟碱的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901248A (en) | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
| DE4002784C1 (pl) | 1990-01-31 | 1991-04-18 | B.A.T. Cigarettenfabriken Gmbh, 2000 Hamburg, De | |
| US5065775A (en) | 1990-02-23 | 1991-11-19 | R. J. Reynolds Tobacco Company | Tobacco processing |
| US5276043A (en) * | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5942244A (en) | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
| EP1083913A4 (en) * | 1998-06-05 | 2004-03-17 | Regent Court Technologies | MONOAMINE OXIDASE (MAO) INHIBITORS AND USES THEREOF |
| US6764826B2 (en) * | 2000-06-08 | 2004-07-20 | Board Of Regents, The University Of Texas System | Inhibitors of C-reactive protein induced inflammation |
| CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| AU2003299933B2 (en) | 2002-10-09 | 2010-06-24 | Luoxis Diagnostics, Inc. | Diagnosis and monitoring of inflammation, ischemia and appendicitis |
| WO2006042192A2 (en) | 2004-10-06 | 2006-04-20 | The Brigham And Womens's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
| US20080003213A1 (en) * | 2006-05-22 | 2008-01-03 | Jan Lessem | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels |
| WO2010030887A1 (en) * | 2008-09-11 | 2010-03-18 | Catholic Healthcare West | Nicotinic attenuation of cns inflammation and autoimmunity |
| US8151804B2 (en) | 2008-12-23 | 2012-04-10 | Williams Jonnie R | Tobacco curing method |
-
2011
- 2011-03-23 WO PCT/US2011/029613 patent/WO2011119722A2/en active Application Filing
- 2011-03-23 EP EP11714880.9A patent/EP2549995B1/en active Active
- 2011-03-23 EP EP19162458.4A patent/EP3524246A1/en not_active Withdrawn
- 2011-03-23 CA CA2794097A patent/CA2794097C/en active Active
- 2011-03-23 EP EP19162452.7A patent/EP3524245A1/en not_active Withdrawn
- 2011-03-23 PT PT117148809T patent/PT2549995T/pt unknown
- 2011-03-23 EP EP21165632.7A patent/EP3871674B1/en active Active
- 2011-03-23 PL PL11714880T patent/PL2549995T3/pl unknown
- 2011-03-23 DK DK11714880.9T patent/DK2549995T3/da active
- 2011-03-23 AU AU2011232478A patent/AU2011232478A1/en not_active Abandoned
- 2011-03-23 ES ES11714880T patent/ES2869851T3/es active Active
-
2017
- 2017-03-08 AU AU2017201593A patent/AU2017201593C1/en active Active
-
2019
- 2019-01-08 AU AU2019200103A patent/AU2019200103B2/en active Active
- 2019-01-08 AU AU2019200102A patent/AU2019200102B2/en active Active
-
2020
- 2020-10-21 AU AU2020257090A patent/AU2020257090B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3871674B1 (en) | 2024-12-25 |
| ES2869851T3 (es) | 2021-10-26 |
| EP3524246A1 (en) | 2019-08-14 |
| WO2011119722A3 (en) | 2011-12-29 |
| EP2549995B1 (en) | 2021-04-21 |
| AU2017201593C1 (en) | 2019-06-27 |
| CA2794097A1 (en) | 2011-09-29 |
| EP2549995A2 (en) | 2013-01-30 |
| EP3524245A1 (en) | 2019-08-14 |
| AU2017201593B2 (en) | 2019-02-28 |
| AU2017201593A1 (en) | 2017-03-30 |
| AU2019200103B2 (en) | 2020-07-30 |
| AU2020257090B2 (en) | 2021-12-02 |
| CA2794097C (en) | 2016-08-09 |
| AU2020257090A1 (en) | 2020-11-19 |
| EP3871674A1 (en) | 2021-09-01 |
| DK2549995T3 (da) | 2021-05-25 |
| EP3871674C0 (en) | 2024-12-25 |
| WO2011119722A2 (en) | 2011-09-29 |
| PT2549995T (pt) | 2021-07-29 |
| AU2019200102A1 (en) | 2019-01-31 |
| AU2019200102B2 (en) | 2020-07-30 |
| AU2019200103A1 (en) | 2019-01-31 |
| AU2011232478A1 (en) | 2015-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2549995T3 (pl) | Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabiny | |
| IL223241A0 (en) | Cysteamine derivatives and their use in the treatment of nash | |
| PL2714006T4 (pl) | Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu | |
| SMT201600430B (it) | Inibitori di chinasi e loro uso nel trattamento del cancro | |
| PL2252283T3 (pl) | Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby | |
| PL3199024T3 (pl) | Zastosowanie kompozycji cyklodekstryny i stosowne sposoby | |
| IL232256A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
| HK1182711A1 (zh) | 作為 抑制劑用於治療癌症的哌啶酮衍生物 | |
| IL226049A0 (en) | Composition for use in the prevention and/or treatment of skin conditions and skin diseases | |
| EP2262469A4 (en) | SKIN CARE COMPOSITIONS AND METHODS OF USE | |
| PL2523678T3 (pl) | Antagoniści Wnt i sposoby leczenia | |
| PL2606120T4 (pl) | Ludzkie komórki ułatwiające tolerancję i ich zastosowanie | |
| HK1180322A1 (zh) | 嘧啶衍生物及其在治療呼吸系統疾病比如 中的用途 | |
| EP2536283A4 (en) | PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR | |
| PL2780036T3 (pl) | Kompozycje nanocząstek do generowania regulatorowych komórek t i leczenie chorób autoimmunologicznych i innych przewlekłych stanów zapalnych | |
| PL3004108T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób | |
| IL223286A0 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| EP2574172A4 (en) | MATERIALS AND METHOD FOR TREATING INFLAMMATION | |
| DK2536748T3 (da) | Neuregulin-antagonister og anvendelse deraf ved behandling af kræft | |
| IL229381B (en) | Brilacitidine and its results for use in the treatment of mucositis | |
| EP2651894A4 (en) | THIOSEMICARBAZONE COMPOUNDS FOR CANCER TREATMENT | |
| IL223175A0 (en) | Tamarind seed polysaccharide for use in the treatment of inflammatory diseases | |
| DK3363437T3 (da) | Aminoindanforbindelser og anvendelse deraf i behandling af smerte | |
| BR112013014915A2 (pt) | composição curativa e métodos de tratamento | |
| PL2614824T3 (pl) | Pochodna triazolowa do stosowania w leczeniu bólu neuropatycznego i fibromialgii |